Esofine-LS Capsule SR is a combination pharmaceutical formulation containing Levosulpiride 75 mg and Esomeprazole 40 mg, designed for the management of gastrointestinal disorders. Levosulpiride, a selective dopamine D2 receptor antagonist, exhibits prokinetic and antiemetic properties by enhancing gastrointestinal motility and modulating central dopaminergic pathways. Esomeprazole, a proton pump inhibitor, effectively suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme in gastric parietal cells, thereby providing symptomatic relief and promoting mucosal healing in acid-related conditions. The sustained-release formulation ensures prolonged therapeutic plasma concentrations, optimizing efficacy and improving patient compliance. Esofine-LS Capsule SR is indicated for the treatment of gastroesophageal reflux disease (GERD), functional dyspepsia, gastritis, and associated motility disorders. It is particularly beneficial in patients presenting with symptoms such as heartburn, epigastric pain, nausea, and bloating. Administration should be as prescribed by a healthcare professional, with consideration for contraindications including hypersensitivity to either component, and caution in patients with renal or hepatic impairment. Common adverse effects may include headache, dizziness, and mild gastrointestinal disturbances. Regular monitoring and adherence to prescribed dosage are essential to maximize therapeutic outcomes and minimize potential risks.